CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS

Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, Kretschmann S, Simon D, Kharboutli S, Mougiakakos D, Krönke G, Andreas M (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 185-185

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.1120

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III Sebastian Böltz Department of Medicine 3 – Rheumatology and Immunology Fabian Müller Department of Medicine 5 – Haematology and Oncology Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology Simon Völkl Department of Medicine 5 – Haematology and Oncology David Simon Department of Medicine 3 – Rheumatology and Immunology Soraya Kharboutli Medizinische Fakultät Gerhard Krönke Professur für Translationale Immunologie

How to cite

APA:

Schett, G., Böltz, S., Müller, F., Kleyer, A., Völkl, S., Aigner, M.,... Andreas, M. (2022). CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS. In ANNALS OF THE RHEUMATIC DISEASES (pp. 185-185). LONDON: BMJ PUBLISHING GROUP.

MLA:

Schett, Georg, et al. "CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022. 185-185.

BibTeX: Download